Neuroprotective FK506 does not alter in vivo nitric oxide production during ischemia and early reperfusion in rats.
about
Ginsenoside rd in experimental stroke: superior neuroprotective efficacy with a wide therapeutic windowNeuroimmunophilin ligands: evaluation of their therapeutic potential for the treatment of neurological disorders.Neuroimmunophilins: novel neuroprotective and neuroregenerative targets.Systematic review and metaanalysis of the efficacy of FK506 in experimental stroke.Posterior Reversible Encephalopathy Syndrome After Transplantation: a Review.Non-invasive evaluation of neuroprotective drug candidates for cerebral infarction by PET imaging of mitochondrial complex-I activity.Dynamics of nitric oxide during simulated ischaemia-reperfusion in rat striatal slices measured using an intrinsic biosensor, soluble guanylyl cyclase.Possible nitric oxide modulation in protective effect of FK-506 against 3-nitropropionic acid-induced behavioral, oxidative, neurochemical, and mitochondrial alterations in rat brain.Neuroprotective action of FK-506 (tacrolimus) after seizures induced with pilocarpine: quantitative and topographic elemental analysis of brain tissue.Neuroimmunophilin ligand V-10,367 is neuroprotective after 24-hour delayed administration in a mouse model of diffuse traumatic brain injury.Effectiveness of FK506 on lipid peroxidation in the spinal cord following experimental traumatic injury.Neuroprotective effects of an immunosuppressant agent on diffusion/perfusion mismatch in transient focal ischemia.Ginkgo biloba extract (EGb761) and FK506 preserve energy metabolites in the striatum during focal cerebral ischemia and reperfusion in gerbils monitored by microdialysis.A novel mechanism of FK506-mediated neuroprotection: downregulation of cytokine expression in glial cells.
P2860
Q24615554-A7D2FEF4-73EC-414E-AFB9-60C3F16CAEF7Q34075121-30490416-6747-44ED-8814-965C578ED991Q34309932-5F1DA1C0-7690-443E-A662-C81967A98E6BQ36036681-A81F783D-EB2E-4E1B-B1AC-A9E36A0A48A8Q38669053-ADC4237C-C800-4872-A1B4-B12D4494AED7Q42032467-9C0451A1-9931-46A9-A25A-27A55FEB0BCAQ42519356-C6F60131-3C21-4FBE-991F-D7422C77CD32Q43021497-DEEE803C-9B61-4728-865B-1558BC299942Q43253697-940182BC-82D1-4D54-9E53-A90FC4573D3DQ44170851-95AF118C-671C-441B-AE07-7A6F87CC0509Q44866378-EA4AE5AA-45DE-41CA-9816-A661F3D37DC2Q44916230-E78BCA8D-4008-4E00-93E0-7DB7763CDBD2Q45021840-ACFA03CA-5758-42E8-9637-A49880F73A3BQ45076802-542B2FBE-86FD-48F3-AD96-F6A702052275
P2860
Neuroprotective FK506 does not alter in vivo nitric oxide production during ischemia and early reperfusion in rats.
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Neuroprotective FK506 does not ...... and early reperfusion in rats.
@ast
Neuroprotective FK506 does not ...... and early reperfusion in rats.
@en
type
label
Neuroprotective FK506 does not ...... and early reperfusion in rats.
@ast
Neuroprotective FK506 does not ...... and early reperfusion in rats.
@en
prefLabel
Neuroprotective FK506 does not ...... and early reperfusion in rats.
@ast
Neuroprotective FK506 does not ...... and early reperfusion in rats.
@en
P2093
P356
P1433
P1476
Neuroprotective FK506 does not ...... and early reperfusion in rats.
@en
P2093
A Bhardwaj
R J Traystman
T M Dawson
V L Dawson
P304
P356
10.1161/01.STR.30.6.1279
P407
P577
1999-06-01T00:00:00Z